Sign in
Taking people in United StatesNo phase

Tests a genetic-review service to guide treatment choice in advanced cancers

Tests a genetic-review navigation service in adults with advanced breast, lung, colorectal or bladder cancer.

Key facts

Who runs it
UNC Lineberger Comprehensive Cancer Center
Where
Chapel Hill, United StatesSee the site
Trial code
Registry title
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Status
Recruiting
People taking part
500 people, planned
Started
27 Jun 2025
Expected to end
Jun 2028
Type of study
Interventional
Treatments tested
  • Expert Review
  • Blood or tissue samples collection.
  • The Precision Oncology Navigation
Record updated
14 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with stage IV lung, colorectal, breast or bladder cancer who can still do most daily activities. A navigator and an expert pharmacist will review their tumor gene test results.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Documented stage IV solid tumor: non-small cell lung cancer, colorectal cancer, breast cancer or bladder cancer.
Earlier treatment
The treating provider plans to use the gene test results in first- or second-line treatment of the metastatic cancer.
Biomarker or test result
A genomic tumor test must not have been ordered yet, or must have been ordered but not yet resulted.

Main reasons for not taking part

  • An active second cancer at the same time

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Written informed consent was obtained to participate in the study and HIPAA authorization for release of personal health information
  • Subjects are willing and able to comply with study procedures based on the judgment of the investigator
  • Age ≥ 18 years at the time of consent
  • ECOG or Karnofsky Performance Status of 0-2
  • Documented Stage IV solid tumor malignancy: NSCLC, CRC, Breast or Bladder Cancer
  • The treating provider deems Next Generation Sequencing (NGS) testing appropriate and plans to consider results in either first- or second-line therapy in the metastatic setting
  • A genomic tumor test has not been ordered or has been ordered but not resulted

Who cannot take part

  • Subjects with an active concurrent malignancy

Other criteria

  • In order to participate in this study a subject must meet all of the eligibility criteria outlined below

Where in United States

  • Lineberger Comprehensive Cancer Center, University of North CarolinaChapel Hill, United StatesContact: Carrie Lee, MDTaking people

About the trial

What the trial wants to find out

This is a hybrid decentralized, single-arm, interventional study designed to evaluate the impact of precision medicine navigation and reflexive expert review of next-generation sequencing (NGS) for patients with stage IV solid tumor malignancies (breast, lung, colorectal, and bladder cancers).

Read full original descriptionShow less

The purpose of this study is to investigate whether intervention from a centralized precision oncology navigator and expert review of NGS results by the precision oncology pharmacist will increase ordering of Level 1/2 genome informed therapy (GIT) compared to an estimated historical rate of 15%. Secondary endpoints will assess the impact of a centralized precision oncology navigator and expert review of NGS results on enrollment in biomarker-directed clinical trials and overall survival at 2 years after return of NGS results. The study will take approximately 12 months for enrolment and 2 years of follow-up after the date of NGS results.

The group in the trial

  • The potential candidates for genome-informed targeted therapyOther group

    Potential candidates have a stage IV solid tumor malignancy (breast, lung, colorectal, and bladder cancer) for whom NGS testing is planned to be obtained before first or second-line therapy.

    Treatment: Expert Review, Blood or tissue samples collection., and The Precision Oncology Navigation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Plain-language title
Tests a genetic-review service to guide treatment choice in advanced cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
14 July 2026